In a Dallas lab, a single human lung cancer sample is revealing the hidden highways of the immune system. Researchers at UT Southwestern Medical Center have developed a powerful new computational tool called ReMiTT—short for Reconstruction of Migration Trails of T cells—that maps the precise paths T cells take as they move through tumor tissue, uncovering clues that could transform how we fight cancer. This breakthrough matters because while T cells are the body’s elite soldiers in the battle against tumors, many cancers erect biological barriers that block their entry or render them ineffective. Understanding how these immune cells navigate—or fail to navigate—within tumors is a critical step toward making immunotherapies work for more patients.
ReMiTT analyzes spatial transcriptomics data, a cutting-edge technique that captures not just which genes are active in a tissue, but exactly where they are expressed. By applying this tool to tumor samples, the team was able to reconstruct migration trails—dynamic pathways showing where T cells have traveled within the tumor microenvironment. In one striking visualization from a lung cancer patient, these trails formed intricate networks across the pathology slide, revealing that signaling molecules like chemokines increase along these routes, effectively lighting the way for immune cells. The researchers also pinpointed specific genes involved in cell adhesion, motility, and extracellular matrix remodeling—biological processes that appear to support T cell movement and function.
The implications are profound. For the first time, scientists can computationally identify where and how T cells migrate within human tumors, offering a new lens to study immune evasion. This could lead to therapies designed not just to boost T cell numbers, but to improve their ability to reach and infiltrate cancerous tissue. As immunotherapy continues to revolutionize oncology, tools like ReMiTT may help explain why some patients respond while others don’t—and how to close that gap.
Published in JCI Insight in 2026, this work led by Lin Zhong and the UT Southwestern team opens a new frontier in cancer immunology. With further validation, ReMiTT could become a standard tool in tumor profiling, helping clinicians tailor treatments based on a tumor’s immune accessibility. The journey of a single T cell through a tumor may now be traceable—and with it, the path to more effective, personalized cancer care.